Finepoint Capital LP Galapagos Nv Transaction History

Finepoint Capital LP

$947 Million
Q1 2025

A detailed history of Finepoint Capital LP transactions in Galapagos Nv stock. As of the latest transaction made, Finepoint Capital LP holds 656,587 shares of GLPG stock, worth $21.1 Million. This represents 1.74% of its overall portfolio holdings.

Number of Shares

656,587

Previous 674,762 2.69%

Holding current value

$21.1 Million

Previous $18.6 Million 11.11%

% of portfolio

1.74%

Previous 1.57%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 14, 2025	SELL	$22.69 - $28.79 $412,390 - $523,258	-18,175 Reduced 2.69%	656,587 $16.5 Million
Q4 2024 Feb 13, 2025	BUY	$25.22 - $31.05 $2.95 Million - $3.63 Million	117,000 Added 20.98%	674,762 $18.6 Million
Q3 2024 Nov 13, 2024	BUY	$24.2 - $30.67 $363,000 - $460,050	15,000 Added 2.76%	557,762 $16.1 Million
Q2 2024 Aug 13, 2024	BUY	$24.78 - $32.48 $966,494 - $1.27 Million	39,003 Added 7.74%	542,762 $13.4 Million
Q1 2024 May 14, 2024	BUY	$32.2 - $42.44 $1.45 Million - $1.91 Million	45,100 Added 9.83%	503,759 $16.2 Million
Q3 2023 Nov 13, 2023	BUY	$34.17 - $42.98 $1.77 Million - $2.23 Million	51,800 Added 12.73%	458,659 $15.8 Million
Q2 2023 Aug 11, 2023	SELL	$37.4 - $44.52 $1.41 Million - $1.68 Million	-37,800 Reduced 8.5%	406,859 $16.5 Million
Q1 2023 May 12, 2023	BUY	$36.5 - $48.0 $1.98 Million - $2.61 Million	54,300 Added 13.91%	444,659 $17.2 Million
Q4 2022 Feb 13, 2023	BUY	$37.44 - $46.51 $398,998 - $495,657	10,657 Added 2.81%	390,359 $17.3 Million
Q3 2022 Nov 10, 2022	BUY	$42.27 - $57.6 $5.09 Million - $6.93 Million	120,302 Added 46.38%	379,702 $16.2 Million
Q2 2022 Aug 12, 2022	BUY	$52.3 - $71.59 $13.6 Million - $18.6 Million	259,400 New	259,400 $14.5 Million

Others Institutions Holding GLPG

# of Institutions

Shares Held

13.4M

Call Options Held

216K

Put Options Held

313K

View Full List

About GALAPAGOS NV

Ticker GLPG
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,835,500
Market Cap $2.12B
Description
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative coliti...

More about GLPG

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Finepoint Capital LP, based on Form 13F filings with the SEC.

News

Stay updated on Finepoint Capital LP with notifications on news.

Account

Finepoint Capital LP Galapagos Nv Transaction History